Study Identifies Predictors of Rapid Renal Decline in ADPKD
Creatinine alone does not reliably predict renal decline in the AKPKD population, according to investigators.
Creatinine alone does not reliably predict renal decline in the AKPKD population, according to investigators.
Autosomal dominant polycystic kidney disease progresses to kidney failure faster in Hispanic patients than in those of other races or ethnicities, a study found.
Nephrologists rarely explained the clinical meaning of rapid progression, according to patients.
Study findings fill an important knowledge gap in ADPKD mortality in the United States, according to researchers.
The early morning fasting urine-to-plasma urea ratio reflects the kidneys’ urine-concentrating capacity, which may decline early in ADPKD, according to investigators.
A study of patients with ADPKD found that each 1 mmol/L decrease in serum bicarbonate was significantly associated with a 21% increased risk for worsening kidney function.
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.
The FDA has granted bardoxolone methyl (bardoxolone; Reata Pharmaceuticals) Orphan Drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD).